Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in hospitalized patients with COVID-19
2020-001517-21Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation including ECMO. Status: unknown.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001517-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001517-21.